FDA Approved: ARIPIPRAZOLE — Supplemental Application (Advagen Pharma Ltd)

View source ↗

Summary

FDA approved Advagen Pharma Ltd's supplemental application for aripiprazole (ARIPIPRAZOLE) under ANDA216351.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder
• Bipolar Disorder
• Major Depressive Disorder
• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• ARIPIPRAZOLE (Aripiprazole)

Snippet

SUPPL AP for ARIPIPRAZOLE (ARIPIPRAZOLE)